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An intensive induction regimen, consisting of idarubicin and high dose cytarabine, was assessed in 19
adult patients, median age 44 years, with newly diagnosed precursor-B acute lymphoblastic leukemia
(ALL). Patients achieving a complete response (CR) were given an attenuated consolidation course. The
primary endpoints were induction death rate and incidence of serious non-hematological toxicity.
Grades 3e4 diarrhoea occurred in 47% of patients during induction. Two patients (11%) died during
induction therapy, and 2 were withdrawn due to resistant disease or prolonged marrow hypoplasia.
Fifteen patients achieved CR (79%), but levels of minimal residual disease (MRD) after induction were
comparable with those previously observed using a modiﬁed pediatric protocol. Overall survival at 5
years was 36.8% while leukemia-free survival was 44.1%. An intensive AML protocol used in adults with
ALL resulted in substantial toxicity and provided similar levels of cytoreduction to conventional ALL
protocols, without improving long-term outcomes.
© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
The treatment of acute lymphoblastic leukemia (ALL) in adults
remains unsatisfactory [1]. Combination chemotherapy protocols
developed for treating children with ALL, and modiﬁed for use in
adults yield less favourable outcomes than in children [2,3].
Although more intensive pediatric protocols have improved out-
comes in adolescents and young adults with ALL, the results are stillNew Zealand Clinical Trials
.
y, Westmead Hospital, Darcy
. Bradstock).
Inc. This is an open access article uinferior to those obtained in children [4e7]. While complex issues
relating to patient treatment compliance, as well as physician and
institutional experience, likely contribute to these outcomes, dif-
ferences in disease biology with increasing age are also a major
factor in determining the higher risk of relapse. This is reﬂected in
higher levels of minimal residual disease (MRD) observed in adults
compared with children after induction therapy, indicating rela-
tively greater inherent disease resistance to initial chemotherapy
[8e11]. One potential way of achieving more rapid early cytor-
eduction would be to escalate the intensity of induction therapy.
We therefore explored whether the use of an intensive combina-
tion chemotherapy protocol designed for the treatment of acute
myeloid leukemia (AML) in adults might result in greater leukemia
cytoreduction, and therefore produce higher response and lower
MRD levels, than traditional modiﬁed pediatric ALL protocolsnder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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results of a Phase-2 trial using an intensive AML protocol, consist-
ing of induction and consolidation with high dose cytarabine and
idarubicin, in newly diagnosed adults with Philadelphia chromo-
some negative precursor B ALL.
2. Patients and methods
2.1. Trial conduct and eligibility
This phase II clinical trial was conducted and sponsored by the
Australasian Leukemia & Lymphoma Group (ALLG) in seven
Australian centres. The trial was registered at
ACTRN12615000631505 and approved by the Human Ethics Com-
mittees of participating centres. All patients gave written informed
consent to participate. Eligibility criteria included a diagnosis of
untreated ALL by WHO criteria, with FAB morphological subtypes
L1 and L2, precursor B phenotype, age 20e55 years inclusive, ECOG
performance status 0e3 and adequate renal and hepatic function.
Patients with T-cell and mature B-cell phenotypes, and patients
with Philadelphia chromosome and/or positivity for BCR-ABL
transcripts, were ineligible. The study opened in June 2002 with a
proposed accrual target of 25 eligible patients, but was closed in
November 2005 due to slower than expected accrual, after 20 pa-
tients had been enrolled.
2.2. Treatment protocol
Induction therapy consisted of cytarabine given as a 2 h intra-
venous infusion of 3 g/m2on day 1, followed by a continuous
intravenous infusion starting 12 h later for 96 h at a dose of 1.5 g/m2
per 24 h, together with idarubicin 12 mg/m [2] IVI daily for the ﬁrst
3 days. Intrathecal methotrexate 12mgwas also given at the start of
induction therapy. Supportive treatment consisted of allopurinol,
ﬂuconazole 200 mg daily, and ﬁlgrastim 5 mg/kg subcutaneously
daily from day 6 until neutrophil recovery to >2.0  109/L. Patients
achieving a complete remission (CR) were given a second attenu-
ated course as consolidation therapy, with cytarabine 3 g/m [2] over
2 h followed by a 72 h infusion at 1.5 g/m2 per 24 h, and idarubicin
12 mg/m [2] IV on days 1 and 2.
Further therapy was not protocol speciﬁed, but it was recom-
mended that patients in ongoing CR should receive high-dose
methotrexate with leucovorin rescue as central nervous system
prophylaxis, and then treatment according to the CALGB 8811
protocol for adult ALL [12].
2.3. Minimal residual disease detection
This was carried out as previously reported [8]. Brieﬂy, DNAwas
extracted from diagnostic bone marrow biopsy samples, and the
complementarity determining regions (CDR) 2 and 3 of the
immunoglobulin heavy chain genewere ampliﬁed using consensus
PCR primers and sequenced using Sanger sequencing. Patient
speciﬁc primers were then designed, and used in a nested PCR to
test for MRD in bone marrow aspirate samples taken at the end of
induction treatment and again after the consolidation course.
2.4. Study endpoints
This study was designed to assess the toxicity and tolerability of
intensive induction chemotherapy for newly diagnosed adult ALL.
The primary endpoints were the induction death rate, deﬁned as
deaths occurring within 28 days of starting induction chemo-
therapy, and the incidence of grade-3 and -4 non-hematological
toxicities, graded according to NCI Common Toxicity Criteriaversion 2.0. Secondary endpoints were the rates of CR after in-
duction and consolidation therapy, overall survival and leukemia-
free survival, and correlation of levels of MRD with clinical out-
comes. CR was deﬁned as: (i) absence of symptoms and signs of
leukemia; (ii) neutrophil count >1.0  109/L at least 5 days after
ceasing ﬁlgrastim; (iii) platelet count >100  109/L; (iv) absence of
leukemic cells in the peripheral blood; and (v) normocellular bone
marrow with active hemopoiesis and <5% blasts. Overall survival
was measured from the date of commencing induction therapy
until the date of death from any cause. For patients who achieved
CR, leukemia-free survival was measured from the date of
achievement of CR until the earlier of the dates of relapse and
death. Patients who underwent allogeneic hemopoietic cell trans-
plantation in ﬁrst remission were censored at the date of
transplant.
2.5. Statistical methods
The induction death rate was calculated as the percentage of
eligible patients who died within 28 days of commencing induction
therapy. Similarly the incidences of grade-3 and -4 non-
hematological toxicities and CR rates were reported for the same
group of patients. Ninety-ﬁve percent conﬁdence intervals (95% CI)
were reported using the Blyth-Still-Casella method.
Overall and leukemia-free survival curves were estimated using
the Kaplan-Meier product limit method, with a close-out date of 28
July 2011. Survival times were censored at the close-out date for
patients alive and leukemia-free at this date or at the date of last
contact for patients lost to follow-up prior to the close-out date.
Median follow-up was estimated by the Reverse Kaplan-Meier
method. Statistical analyses were carried out using SAS, R version
2.15.2 and StatXact statistical software.
The statistical software SPSS version 21 was used to analyse the
post-induction MRD data. Two-tailed tests with a signiﬁcance level
of 5% were used throughout. MRD levels were log transformed to
approximate normality prior to analysis. Cox proportional hazards
regression was used to test for association between post-induction
MRD levels and leukemia-free survival. The independent two-
sample t-test was used to test for differences in MRD levels be-
tween this patient group and a historical cohort of 29 adult patients
treated with a standard modiﬁed pediatric ALL protocol [8].
3. Results
3.1. Patient characteristics (Table 1)
A total of 20 patients were registered between June 2002 and
March 2005, with one excluded because of Philadelphia chromo-
some positivity. Therefore 19 eligible patients started protocol
therapy. A second patient (case 16) was subsequently found to be
Philadelphia chromosome-positive and was withdrawn after
completing induction, but was included in the analysis of the pri-
mary endpoint.
Patients were aged 21 to 55 (median 44) years. There were 12
(63%) males. None had evidence of CNS leukemia. The median
peripheral blood white cell count was 9.8  109/L (range 0.2e251),
and median percentage blasts in the marrow was 91 (range
10e100). Cytogenetic analysis showed an abnormal karyotype in 10
patients, one each of; t(4;11), t(1;19), t(9;22), hypodiploid, high
hyperdiploidy, and complex karyotype, and four others had other
abnormalities (including three with hyperdipoidy 47e50).
3.2. Outcome of induction therapy (Fig. 1)
Of the 19 patients, 17 received 90% of the protocol dose of
Table 1
Patients baseline characteristics.
Characteristic Evaluable patients
n %
Total 19 100
Sex Male 12 63
Female 7 37
Age (years) at registration Median 44
Mean (SD) 39 (12)
Range 21e55
<30 5 26
30e39 4 21
40e49 5 26
50e55 5 26
ECOG performance status 0 6 32
1 11 58
2 2 11
Febrile (38 C) No 14 74
Yes 5 26
Clinically evident infection No 17 89
Yes 2 11
FAB classiﬁcation L1 6 32
L2 13 68
Presentation WCC (109/L) Median 9.8 Range 0.2e251
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received the full amount of cytarabine, with 1 patient receiving 75%
of the planned infusional dose.
Two patients (11%; 95% CI: 2%e32%) died of treatment-related
complications and infection within one month. During induction
therapy, fourteen patients (74%; 95% CI: 50%e89%) had NCI-CTC
grades 3e4 neutropenic fevers, while 8 (42%; 95% CI: 22%e66%)
had grades 3e4 bleeding. Other grades 3e4 toxicities included 9
(47%; 95% CI: 24%e69%) patients with diarrhoea, 3 (16%; 95% CI:
4%e38%) with stomatitis, and 3 (16%; 95% CI: 4%e38%) with skin
rash. One additional patient developed neutropenic enterocolitis.
Of the 19 patients starting induction therapy, 15 achieved CR
(79%; 95% CI: 57%e92%). Two patients died before day 28 of
treatment complications, 1 patient had residual leukemia, and 1
patient hadmarrow hypoplasia without evidence of leukemia. Both
of the latter were withdrawn from the study.20 enro
19 patients 
induction t
17 evaluable fo
15 complete 
4 patients in co
complete remission
4 BMT in CR1 #4, 15, 17, 20
Fig. 1. Patient ﬂow d3.3. Subsequent outcome
All 14 eligible patients achieving CR received the scheduled
course of consolidation therapy (case 16 was withdrawn), with no
treatment-related deaths. Four patients subsequently underwent
allogeneic hemopoietic cell transplant in ﬁrst remission; 1 of these
patients relapsed and died post-transplant, while the remaining 3
remained alive and leukemia-free. Of the 10 patients not trans-
planted, 6 had bone marrow relapse; 1 of these had an allogeneic
transplant in second remission and subsequently died of graft-
versus-host disease, while the other 5 died of progressive leuke-
mia. Four patients remained in continuous CR without allogeneic
transplant at the study close-out date.
The median follow-up was 7.8 (range 6.1e8.6) years for survi-
vors. The median overall survival was 3.0 years, with observed
survival rates of 68.4% (95% CI: 45.2%e85.1%) at 1 year, 52.6% (95%
CI: 31.1%e73.2%) at 2 years, and 36.8% (95% CI: 18.7%e59.7%) at 5
years (Fig. 2). Corresponding leukemia-free survival rates were
66.1% (95% CI: 35.8%e87.2%) at 1 year; 55.1% (95% CI: 26.3%e80.9%)
at 2 years; and 44.1% (95% CI: 18.2%e73.6%) at 5 years (Fig. 3).3.4. Association between MRD levels and clinical outcomes
Data on post-induction treatment residual disease levels were
available on 9 of 16 assessable patients. Of these, MRD levels ranged
from <1.2  106 to 1.2  102. Two patients had a transplant in
ﬁrst remission, while of the 7 non-transplanted patients 5 relapsed
and 2 remain in CR. The MRD levels in post-induction samples in
these 9 patients were compared to the levels previously reported in
27 adult patients treated with a protocol based on a modiﬁed pe-
diatric regimen [8]. Using a 2 tailed t-test for equality of means,
there was no signiﬁcant difference in MRD levels between the 2
groups (mean log (MRD day 28)± SD for current study3.76± 1.33,
for historical control group 3.17 ± 1.30) (p ¼ 0.243) (Fig. 4).4. Discussion
The purpose of the study was to administer an intensive AML
remission induction regimen based on high-dose cytarabine to
adult patients with newly diagnosed precursor B ALL, with thelled
1 excluded
Ph+ #6
started 
herapy 2 induction deaths #2, 8
r response
1 hypocellular, off protocol #1
1 residual disease, BMT #18
remission 1 withdrawn Ph+ # 16
ntinuing 
 #5, 9, 10, 13
6 relapses #3, 7 11, 12, 14, 19
(1 BMT #11)
iagram for trial.
Fig. 2. Overall survival for eligible study patients.
Fig. 3. Leukemia-free survival for eligible study patients achieving CR.
Fig. 4. Comparison of post-induction MRD levels between historical cohort of patients
using modiﬁed pediatric ALL protocol [8] (group 1) and 9 assessable cases enrolled on
current study (group 2).
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thereby reducing the subsequent relapse risk. This was based on
the known association between the achievement of low or negative
MRD levels after induction therapy in both ALL and AML, and
subsequent superior long-term leukemia-free survival [8e11,13].
We used a regimen consisting of infusional high-dose cytarabine
and idarubicin in a schedule similar to that described for treatment
of adult AML [14]. Although there was only 1 case of resistant
disease, the CR rate, based on intention to treat, was only 79% and
was broadly comparable with current ALL protocols used in adults.
The regimen was toxic, with 11% death rate during induction
therapy and substantial levels of grades 3e4 non-hematologic
toxicity, particularly gastrointestinal.
We measured MRD levels in post-induction marrow samples
using sensitive PCR technology to directly assess cytoreduction.Although 7 of 9 patients evaluated had MRD levels below 104, 2
had high levels and relapsed 2 and 8 months after start of treat-
ment. When we compared these MRD levels with those in a his-
torical cohort of adult patients treated on a modiﬁed pediatric
protocol, there was no signiﬁcant difference between the 2 groups,
suggesting that the more intensive AML regimen in fact did not
produce materially greater cytoreduction compared with the more
traditional adult ALL protocol.
High-dose cytarabine has efﬁcacy in relapsed ALL and is widely
used in this setting. However, there are only a limited number of
reports of its use in initial therapy of newly diagnosed adult ALL
[15e18]. Willemze and colleagues used intermediate-dose cytar-
abine (1 g/m2  12 doses), together with etoposide, amsacrine, and
prednisone in 32 patients with ALL [15]. There were 23 CR (72%),
and overall survival at 5 years was 38%. Ifrah et al. treated 67 adults
with cytarabine 1 g/m2 for 6 doses, together with idarubicin and
methylprednisolone [16]. Of 64 eligible cases, 50 achieved CR (78%),
with 4 year overall survival 24%. Hallbook and colleagues treated
153 adults with ALL with cytarabine 3 g/m2 for 6 doses, together
with daunorubicin, cyclophosphamide, vincristine and betame-
thasone [17]. The CR rate was 90%, but overall survival at 3 years
was only 29%, although 62% in a subgroup aged less than 40 years
with precursor B disease. Finally, Lamanna and colleagues reported
a multicentre US trial in adult ALL, comparing the L-20 protocol
with the ALL2 protocol, consisting of cytarabine 3 g/m2 daily for 5
days combinedwith a single high dose of mitoxantrone [18]. The CR
rate was signiﬁcantly higher with ALL2 compared with L-20 (83%
versus 71%), with 9% induction deaths and 8% resistant disease, but
only 34% 5 year survival. This latter study most closely approxi-
mated our own trial design, with no lympholytic drugs such as
prednisone or vincristine used in induction. Results of our study
approximate those of the US trial, with CR rate of 79%, and 5 year
overall survival 37%, and leukemia-free survival 44%.
In conclusion, high-dose cytarabine and idarubicin for treat-
ment of newly diagnosed precursor B ALL in adults demonstrated
an acceptable CR rate, but with signiﬁcant non-hematologic
toxicity. The levels of MRD following the induction cycle were not
signiﬁcantly different from those using a more traditional modiﬁed
pediatric protocol, and long-term outcomes were also comparable.
More intensive pediatric protocols have been reported to improve
outcomes for younger adults with ALL [7,8], and may be preferable.
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